This move is archived. Current quotes and coverage live on the stock page.
Follow DXCM
Dexcom Inc. (NASDAQ:DXCM) is seeing a drop in its stock price, which reflects investor concerns despite a recent positive earnings report.
Today, Dexcom's stock fell by 1.82%, closing at CA$87.90. This decline follows a strong earnings report that initially boosted investor confidence.
Investor takeaway: Even with solid earnings, Dexcom's stock is under pressure, highlighting the volatility in the healthcare sector and potential challenges ahead.
DexCom Inc
DXCM.US
DXCM.US
DexCom Inc
WealthAwesomeMarket cap
$30.94B
P/E
32.7x
52W high
$92.59
52W low
$54.11
1W change
+5.61%
Beta
1.44
Analyst Price Targets
Based on 29 analysts covering DXCM · as of Nov 3, 2026
Wall Street analysts forecast DXCM stock price to rise 18.3% over the next 12 months.
Consensus
Strong Buy4.66 / 5.00
Avg. Target
C$98.15
+18.3% Upside
Previously C$97.23 on Nov 2, 2026
Current Price
C$82.97
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on DXCM's historical volatility
30-Day Vol
34.7%
Annualized
90-Day Vol
39.5%
Annualized
Trend (90d)
-23.0%
Annualized drift
90d Mean
C$76.41
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$80.72 | C$71.62 – C$90.99 |
| 60 trading days | C$78.54 | C$66.31 – C$93.02 |
| 90 trading days | C$76.41 | C$62.11 – C$94.01 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Dexcom reported a 13.1% year-on-year increase in revenues, surpassing analysts' expectations. The company remains a leader in the continuous glucose monitoring market, which is projected to grow significantly in the coming years.
Bear case
The recent decline in stock price may reflect investor worries about pricing pressures and competition within the healthcare sector. Competitors like iRhythm are reporting stronger earnings and better market performance, which could be affecting sentiment around Dexcom.
Earnings Performance
Dexcom's revenues for the quarter reached $1.31 billion, marking a 13.1% increase compared to last year. Although this performance exceeded expectations, the muted stock reaction suggests concerns about future growth.
Market Context
The healthcare sector has experienced mixed results lately, with companies like iRhythm showing stronger outcomes. This may have contributed to the bearish sentiment surrounding Dexcom's stock as investors consider the competitive landscape.
Looking Ahead
Investors will closely monitor how Dexcom addresses its competitive challenges and whether it can sustain its growth amid rising market pressures. The company's ability to innovate and adapt to industry trends will be crucial in the upcoming quarters.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
